Document is current
Any future updates will be listed below
-
Authors
Hu, Xingsheng
Cui, Xinge
Wang, Ziping
Liu, Yunpeng
Luo, Ying
Zhong, Wei
Zhao, Hui
Yao, Mengxing
Jiang, Da
Wang, Mingxia
Chen, Minjiang
Zheng, Xin
Ding, Lieming
Wang, Yang
Yuan, Xiaobin
Wu, Pengxiang
Hu, Bei
Han, Xiaohong
Shi, Yuankai
-
Funding
Funding for this research was provided by:
Betta Pharmaceuticals
- License Information
-
More Information
Article History
Received: 9 September 2022
Accepted: 30 December 2022
First Online: 11 April 2023
Declarations
:
: The present study protocols were approved by the ethics committees of each involved hospital (Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Cancer Hospital; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; The First Hospital of China Medical University; The Second Affiliated Hospital of Anhui Medical University; and Hebei Tumor Hospital) in accordance with the Declaration of Helsinki. Patients provided informed consent to participate in this study.
: Not applicable.
: This study receives research sponsorship from Hangzhou Betta Pharmaceuticals Co., Ltd, Hangzhou, China. The other authors report no conflicts related to the current manuscript.
